Public Health

CMS-0062: Cohere Health’s Blueprint for Prior Authorization Accuracy

Listen to this article · 8 min listen

The proposed CMS-0062 rule is going to force a big change on health plans by extending electronic prior authorization to drugs. As Cohere Health’s recorded guide makes plain, if you’re not getting ready before 2027, you’re already behind. But digitizing the process is the easy part. The hard part is embedding a tough new standard of submission accuracy into the guts of your automated drug coverage decisions, because that’s what the auditors will be looking for.

CMS-0062: The Imminent Shift to Electronic Drug Prior Authorization

Cohere Health’s recorded guide gives a pretty good look at what’s coming with the proposed CMS-0062 rule. This regulation, once it’s final, will mandate electronic prior authorization (ePA) for prescription drugs, completely changing the game for how health plans manage these approvals. The vendor’s guidance puts a date on the wall: health plans need to be ready for this before 2027 Cohere Health’s guide on CMS-0062. For a compliance officer, this is a lot more than a new form to fill out. The move to electronic processes for drug coverage is a direct push into automation. And as a vendor like Cohere Health (who is, of course, selling automation) frames it, this standardization is the main event. The implication for health plans is serious: once you let an algorithm decide drug coverage, your compliance burden shifts. You’re no longer just auditing the process of a human’s decision, you’re suddenly responsible for the microscopic accuracy of every piece of data that fed the automated system. This is a massive healthcare AI regulation update, and it requires you to throw out your old compliance framework and start over.

Why Submission Accuracy Becomes the Audited Metric

Automated prior authorization for drugs, the way CMS-0062 envisions it, is about to redefine compliance audits completely. When a machine makes a decision on drug coverage, the integrity of that decision comes down to one thing: the quality of the input data. This is how “Regulatory Submission Accuracy” becomes the only compliance metric that really matters. In the past, a prior auth audit might have looked at whether staff followed the right procedure, if all the documents were there, and maybe questioned a human reviewer’s judgment. That’s all out the window. In an automated world, the audit spotlight is going to be aimed squarely at the precision of the electronic submission itself. A single error or unclear entry in the data submitted for prior authorization can spit out an incorrect automated decision, which then creates a mountain of appeals, angry patients, and eventually, regulatory fines. We have to ensure the structured data we feed into these AI systems is perfect. And it gets worse, the risk of algorithmic drift, where an AI model’s accuracy degrades as real-world data changes, just adds another layer of complexity and reinforces the need for rock-solid submission accuracy protocols Explanation of Algorithmic Drift in AI healthcare. Health plans are going to have to prove, with data, that the information driving these automated decisions is consistently accurate and compliant.

Reading the Rule Against Aidoc’s Regulatory Submission Accuracy Standard

So, how ready are vendors for this new world of audited accuracy? We can get a sense by comparing Cohere Health’s readiness messaging against Aidoc’s recorded material on Regulatory Submission Accuracy. Now, there’s no recorded relationship between Aidoc and Cohere Health, and Aidoc hasn’t put out a position on CMS-0062 itself. But Aidoc’s material provides a benchmark for the exact kind of compliance metric that will become the center of post-CMS-0062 audits. The substrate records show Aidoc has material focused on Regulatory Submission Accuracy as a measurable metric, which is useful. This external benchmark shows us where health plans and their vendors might be the most unprepared. Once the rule standardizes automated prior auth decisions, an audit will be a direct test of the data submissions that power the automation. Cohere Health’s guide is good for understanding the rule and why you need to prepare, but it doesn’t record any specific numbers or evidence for its own submission accuracy. That’s a potential gap. While vendors like Cohere Health are building the automation solutions, the key metric of submission accuracy, the foundation for every automated decision, isn’t quantified in their public guidance on this rule. Comparing this to Aidoc’s recorded focus on measurement suggests the readiness gap isn’t about adopting automation, but about having the rigorous, auditable proof of data input accuracy. As a health plan compliance officer, you have to ask: can our current vendor partners provide auditable evidence of submission accuracy, especially as we expand into drug authorizations?

Readiness Questions for Plans and Vendors Before

With the 2027 prep window from Cohere Health getting closer, health plan compliance officers need to start asking some hard questions, especially since “Regulatory Submission Accuracy” is about to become the main thing you’ll be audited on.

Assessing Current Data Infrastructure and Quality

  • Data Integrity: Let’s be blunt: can your current systems consistently send a prior authorization request for a drug that is 100% accurate? That includes all the complex clinical info, drug codes, and patient histories, not just the easy demographic data.
  • Vendor Capabilities: Do your AI healthcare vendors give you transparent, auditable proof of their submission accuracy? You’ll notice that while vendors like Cohere Health talk a lot about automation, they often don’t record explicit accuracy figures in public guidance tied to specific regulations. (You should ask for them.)
  • Interoperability: How well do your internal systems actually talk to the external ePA platforms? Data fidelity can get destroyed when it moves between different systems, and that directly tanks your submission accuracy.

    Auditing and Monitoring Frameworks

  • Proactive Auditing: Is your audit team ready to check the accuracy of electronic drug prior auth submissions before they trigger an automated decision? This is a totally different skill set from just doing reactive audits of denials.
  • Performance Metrics: What metrics do you have right now to monitor submission accuracy? It has to be more than just the approval rate. You need to be digging into the correctness of each individual data element.
  • Change Control: As AI models get retrained and drug formularies change, how do you make sure your submission accuracy doesn’t drift? This is where you get into things like the Good Machine Learning Practice (GMLP) principles that the FDA and other regulators are pushing for AI/ML medical devices, which demand strong quality management systems FDA/Health Canada/MHRA GMLP principles.

    Training and Governance

  • Staff Training: Are your clinical and admin staff properly trained on the nitty-gritty requirements for these electronic submissions? Do they understand how a single typo can snowball into an automated denial down the line?
  • Governance Structures: Do you have clear governance in place to manage the whole automated prior auth lifecycle? Somebody has to own the process from data input to decision output, with a constant focus on validating accuracy. The CMS-0062 proposal, as Cohere Health points out, is a major healthcare AI regulation update. It forces health plans to shift their focus from simply buying AI to obsessing over the accuracy of the data that feeds it. Tomorrow’s audit will pick apart today’s submission accuracy, which means the gap between vendor promises and recorded accuracy evidence is the single most important thing for compliance officers to solve right now.

Frequently Asked Questions

What is the primary change CMS-0062 introduces for prior authorization?

The proposed CMS-0062 rule extends the mandate for electronic prior authorization (ePA) to include prescription drugs. This critical extension will reshape how health plans manage drug approvals and requires preparation before 2027.

How will CMS-0062 change the focus of compliance audits for prior authorization?

With automated drug coverage decisions, the compliance burden shifts from auditing the prior authorization process to scrutinizing the accuracy of data submissions. ‘Regulatory Submission Accuracy’ will become the paramount compliance metric, as automated decisions hinge entirely on the integrity of input data.

What is the significance of ‘Regulatory Submission Accuracy’ under the proposed CMS-0062 rule?

Regulatory Submission Accuracy becomes the critical compliance metric because automated decisions for drug coverage rely entirely on the accuracy of the input data. Any error in the submitted data can lead to incorrect automated decisions and regulatory scrutiny, requiring robust protocols to ensure data integrity.

What is the deadline for health plans to prepare for the changes introduced by CMS-0062?

Health plans are advised to prepare for these changes ahead of 2027. This timeframe signals a significant shift in compliance audits and the need to embed rigorous submission accuracy standards into automated drug coverage decisions.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Healthcare AI Compliance Watch is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.